Epocrates should be bought on recent weakness, says Piper Jaffray

theflyonthewall.com

Piper Jaffray recommends buying shares of Epocrates on the recent weakness and reiterates an Overweight rating on the name. Piper thinks management presentations at investor conferences in early January will provide catalysts for the stock.

Rates

View Comments (0)